Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [1]
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
Links
[1] https://www.ctsnet.org/jans/neoadjuvant-nivolumab-plus-chemotherapy-resectable-lung-cancer
[2] https://www.ctsnet.org/home/aprotopapas
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2202170?query=TOC&cid=NEJM%20eToc%2C%20May%2026%2C%202022%20DM1081728_NEJM_Non_Subscriber&bid=993524954
[4] https://www.ctsnet.org/tags/basic-science
[5] https://www.ctsnet.org/taxonomy/clinical-epidemiology
[6] https://www.ctsnet.org/taxonomy/molecular-biology
[7] https://www.ctsnet.org/taxonomy/pharmacology
[8] https://www.ctsnet.org/tags/cancer
[9] https://www.ctsnet.org/tags/lung
[10] https://www.ctsnet.org/tags/lung-cancer
[11] https://www.ctsnet.org/taxonomy/lung-cancer-chemotherapy
[12] https://www.ctsnet.org/taxonomy/lung-cancer-molecular-markers
[13] https://www.ctsnet.org/taxonomy/lung-cancer-multimodality-therapy
[14] https://www.ctsnet.org/categories/thoracic
[15] https://www.ctsnet.org/taxonomy2018/medical-technology
[16] https://www.ctsnet.org/taxonomy2018/basic-science